TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

Robert J Motzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.